The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
NuvaRing is the first monthly vaginal ring approved for birth
control. It is a flexible, transparent ring that provides
month-long contraceptive protection through the continuous release
of estrogen and progestin over a 21 day period of use.
NuvaRing conveniently fits into a woman's active lifestyle.
It is simply inserted once a month, removing any daily worries over
birth control. As exact positioning is not critical, NuvaRing
cannot be inserted incorrectly.
As with use of other combination hormonal contraceptives, women
using NuvaRing are strongly advised against smoking.
Approval of NuvaRing is based on positive results from two
larger clinical trials conducted worldwide with 2,322 women who
were exposed to 23,289 cycles of NuvaRing. Pregnancy rates were
between one and two percent.
Adverse events associated with the use of NuvaRing may include
(but are not limited to) the following:
- Upper respiratory tract infection
- Weight gain
Mechanism of Action
NuvaRing releases a continuous low dose of ethinyl estadiol, an
estrogen, and etonogestrel, a progestin. Combination contraceptives
work through the suppression of gonadotropins. Their primary
function is the inhibition of ovulation; such contraceptives also
alter the cervical mucus, which increases the difficulty of sperm
entry to the uterus. Progesterone also makes the endometrium less
favorable for implantation.
For additional information on Nuvaring, please visit